Ernst Hund

Ernst Hund

Auto-generated profile, based on publicly available information

Ernst Hund

Amyloidosis Center, Heidelberg University Hospital, and Faculty of Medicine, Heidelberg University, Heidelberg, Germany

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 December 2020 in Amyloid
Verified
Journal Article
Open access
MUMatthias N. Ungerer
Matthias N. Ungerer
EHErnst Hund
Ernst Hund
JPJan Purrucker
Jan Purrucker
LHLaura Huber
Laura Huber
CKChristoph Kimmich
Christoph Kimmich
MWMarkus Weiler
Markus Weiler
Hereditary transthyretin amyloidosis is caused by pathogenic variants in the TTR gene and typically manifests, alongside cardiac and other organ dysfunctions, with a rapidly progressive sensorimoto...

16 October 2008
Verified
Book Chapter
Closed access
PDF file
RGR. Gold
R. Gold
WMW. Müllges
W. Müllges
HHH. -C. Hansen
H. -C. Hansen
MAM. Anetseder
M. Anetseder
TMT. Metterlein
T. Metterlein
KTK. V. Toyka
K. V. Toyka

11 August 2026 in Neurological Research and Practice
Verified
Journal Article
Open access
PDF file
MWMarkus Weiler
Markus Weiler
MDMaike Dohrn
Maike Dohrn
SGStefan Gingele
Stefan Gingele
Thomas SkripuletzThomas Skripuletz
Thomas Skripuletz
MSMatthias Schilling
Matthias Schilling
KHKatrin Hahn
Katrin Hahn
Hereditary transthyretin (ATTRv) amyloidosis is a rare, progressive multisystem disease caused by pathogenic variants in the transthyretin ( TTR ) gene. ATTRv-associated Polyneuropathy (ATTRv-PN) manifests in a length-dependent sensorimotor and autonomic pattern, commonly accompanied by cardiomyopathy. In recent years, clinical trials have introduced two classes of disease modifying treatments (DMT), TTR stabilizers and gene silencers. Across populations and outcome parameters, all trials share one result disease progression was significantly slowed and patients’ span and quality of life substantially improved compared to placebo, even though a function once lost would not be retrieved. This expert consensus paper provides recommendations for the treatment of ATTRv-PN in Germany and was jointly developed by experts from the German Society of Amyloid Diseases (DGAK) and the German Neurological Society (DGN). In addition to evidence from pivotal clinical trials, the recommendations incorporate benefit assessments of the German Federal Joint Committee (G-BA). For first-line treatment, the DGAK/DGN recommends one of the two second-generation TTR gene-silencing agents, vutrisiran or eplontersen, for most patients with symptomatic ATTRv-PN. For patients showing even minor signs of disease progression under a TTR stabilizer, the authors recommend immediate switch to a gene silencer. Evidence is limited for or against switching between silencers or combining different agents. Informed patient participation is crucial upon initiation and adaptation of DMT. For central nervous system (CNS) involvement, none of the approved agents sufficiently crosses the blood-brain barrier. Aligned with that, there are no observed or expected CNS side effects of any of the DMTs. In the future, next-generation RNA-interference therapies, gene-editing approaches, and amyloid-depleting antibodies are expected to further expand therapeutic options.

15 December 2025 in DGNeurologie
Verified
Journal Article
Open access
PDF file
UMU. M. Mayer
U. M. Mayer
HPHelena Franziska Pernice
Helena Franziska Pernice
SGStefan Gingele
Stefan Gingele
JSJ. Sachau
J. Sachau
SISandra Ihne
Sandra Ihne
MDMaike Dohrn
Maike Dohrn